Executive Management

Mr. Burns has served as our chief executive officer and as a member of our Board of Directors since March 2002. In December 2021, he was appointed Chairman of the Board. He also previously served as our president from March 2002 to March 2022. Mr. Burns was also a founder and member of the board of directors of DOSE Medical Corporation (acquired by Glaukos), serving as its chairman of the board from October 2009 until June 2019 and its chief executive officer and president from March 2010 until June 2015. Mr. Burns has a proven record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. He has raised nearly $400 million in enterprise capital in private and public offerings and has led and helped build multiple start-up companies. Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices and pharmaceuticals, drug delivery technologies, surgical products and over-the-counter products. Prior to joining our Company, Mr. Burns led Eyetech Pharmaceuticals, Inc. (acquired by OSI Pharmaceuticals, Inc.) as its president and chief operating officer and as a director. From 1990 to 1997, Mr. Burns served as senior vice president and general manager of Chiron Vision Corporation (acquired by Bausch & Lomb, Inc.), and then as vice president, global strategy and general manager, refractive surgery, of Bausch & Lomb from 1998 to 2000. In October 2020, Mr. Burns joined the board of directors of Pulmonx Corporation (Nasdaq: LUNG). He served on the board of directors of Avedro from July 2018 until his resignation on August 6, 2019, prior to its acquisition by Glaukos. Mr. Burns has also served as an entrepreneur in residence at Versant Ventures Management, LLC. Mr. Burns received a B.A. from Yale University.

Mr. Gilliam has served as our president and chief operating officer since April 2022. He previously served as our chief financial officer and senior vice president, corporate development since joining Glaukos in May 2017. Mr. Gilliam has nearly 20 years of experience across capital markets, strategic advisory, finance and banking services with an emphasis on the life sciences industry, including the medical technology, diagnostics and biotechnology sectors. From 2013 to May 2017, he was a managing director in the healthcare investment banking group at JPMorgan, where he led the Glaukos initial public offering for the firm. From 2001 to 2013, Mr. Gilliam held increasingly responsible positions at JPMorgan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bond offerings and other transactions. His prior experience includes positions at The Beacon Group (which was combined with JPMorgan and Chase Manhattan in 2001) and PricewaterhouseCoopers. Mr. Gilliam currently sits on the board of directors of Caris Life Sciences. Mr. Gilliam has a B.S. in accounting from the Kelly School of Business at Indiana University.

Dr. Navratil has served as our chief development officer since April 2022. He previously served as our senior vice president, research and development since joining Glaukos in October 2020. Dr. Navratil has 20+ years of experience in ophthalmic drug and medical device R&D and regulatory affairs spanning new chemical entities, novel medical devices, sustained release drugs and novel routes of administration, Phase 1-4 clinical programs, and regulatory submissions to the U.S. Food & Drug Administration, the European Medicines Agency, and regulatory authorities in Asia Pacific. From 2017 to October 2020, Dr. Navratil served in several leadership positions at the Nicox group, including general manager of Nicox Ophthalmics, Inc. and executive vice president and global head of R&D for Nicox S.A. Prior to joining Nicox, he served as senior vice president of development at Envisia Therapeutics. Prior to Envisia Therapeutics, Dr. Navratil held several director-level positions in drug discovery, clinical research and development, and medical affairs at Liquidia Technologies, Parion Sciences and Inspire Pharmaceuticals. He has been issued multiple patents and authored multiple publications on ocular and pulmonary drug delivery and product development. Dr. Navratil was a Morehead Scholar and received his B.S. and Ph.D. in chemistry from the University of North Carolina at Chapel Hill.

Mr. Thurman has served as our senior vice president and chief financial officer since April 2022. He initially joined Glaukos in July 2016 as vice president, global tax and administration and then served as our vice president, finance from December 2016 to April 2022. Mr. Thurman has been instrumental in assembling the company’s finance organization by overseeing significant growth of the finance and accounting teams while building out the financial infrastructure to serve both the U.S. and 16 international direct sales markets, navigating the transition to Sarbanes-Oxley compliance and the associated development of our internal audit function, and overseeing our global information technology group. Prior to Glaukos, he held increasingly responsible financial and tax leadership positions over 20 years at Allergan, Inc., Deloitte and Arthur Andersen. Mr. Thurman has both a B.S. in accounting and Master of Accountancy in Tax from the Marriott School of Management at Brigham Young University and received a CPA license (inactive) from the state of California.

Michele M. Allegretto has served as our senior vice president, human resources since April 2019. She was previously our vice president, human resources, a position she had held since joining Glaukos in May 2015. From October 2005 to May 2015, Ms. Allegretto served as director global business human resources with Abbott Medical Optics, a global ophthalmic medical device division of Abbott Laboratories. From January 2002 to October 2005, Ms. Allegretto was director of human resources for The Wet Seal, Inc., a publicly traded national women’s retail chain. From April 1995 to December 2001, Ms. Allegretto served in several different leadership positions across three divisions of The Walt Disney Company, including the director recruitment for Walt Disney Studios. Ms. Allegretto holds a B.A. from San Diego State University and a master’s degree from California State University, Long Beach.

Robert L. Davis has served as our senior vice president, general counsel and business development since August 2023, after also serving as senior vice president, general counsel from June 2015 to June 2020. From April 2008 to May 2015, Mr. Davis served as senior vice president, general counsel and secretary for Targus Group International, Inc., a global designer, manufacturer and distributor of cases and accessories for mobile electronic devices. From March 2003 to April 2008, Mr. Davis served as a senior vice president of corporate development of Meade Instruments Corp. He previously served as Meade’s senior vice president of sales from July 2006 to April 2008, and as a vice president and an assistant general counsel since December 1999. He served as an attorney of O’Melveny & Myers LLP from September 1996 to December 1999 specializing in corporate and securities law. He worked as an attorney of Morrison & Foerster LLP from August 1994 to September 1996 specializing in corporate finance and labor and employment law. He received a BA degree in English and a JD degree from Brigham Young University.

Tracy M. Founds has served as our senior vice president, global quality and medical safety since April 2024. She previously served as our vice president, global quality and medical safety since joining Glaukos in June 2021. From August 2020 to May 2021, Ms. Founds served as associate vice president at AbbVie, where she was responsible for the integration of Allergan global quality functions into the AbbVie quality team. From January 2018 to May 2020, she served as associate vice president, digital transformation quality at Allergan. From January 2015 to December 2018, Ms. Founds served as associate vice president, post marketing quality at Allergan (previously Actavis). From January 2010 to December 2014, she served as director, quality operations for Forest Pharmaceuticals (acquired by Actavis). Her prior industry experiences include leadership positions in quality at Covidien, Boehringer Ingelheim (Ben Venue), and ABC Laboratories. Ms. Founds holds a B.S. in both Biology and Chemistry from the University of Southern Indiana, a Master of Health Administration (MHA) from the University of Missouri – Columbia, and an M.S. in Jurisprudence (MSJ) from Seton Hall Law School.

Dr. Katz has served as our Chief Medical Officer since February 2017. He is currently employed by our company on a part-time basis while maintaining his Philadelphia-based ophthalmology practice and involvement in clinical research and medical education. Dr. Katz completed his glaucoma fellowship at Wills Eye Hospital in Philadelphia in 1985 and has been affiliated with the hospital since that time, currently serving as its director of glaucoma service. Since 1997, he has also served as a professor of ophthalmology at Jefferson Medical College at Thomas Jefferson University. He is a former member of the board and past treasurer of the American Glaucoma Society, a diplomate and associate examiner for the American Board of Ophthalmology and a fellow, member-at-large and past president of the Philadelphia Metro chapter of the American College of Surgeons. He has published more than 200 articles in ophthalmic journals and served as an investigator in landmark glaucoma trials, including the Advanced Glaucoma Intervention Study (AGIS) and Collaborative Initial Glaucoma Treatment Study (CIGTS). Dr. Katz completed his residency at Yale University and internship at the University of Virginia after earning his M.D. from Yale University Medical School. He holds a B.A. (summa cum laude) from Case Western Reserve University.

Dr. Szekely has served as our vice president, research and development, combination pharmaceutical products since September 2018. She previously served as our vice president, translational sciences since joining Glaukos in 2015. Dr. Szekely has over 20 years of experience in pharmaceutical drug development and life sciences industry product development. Between 2008 and 2015, she held positions of increasing responsibilities at Allergan, most recent being vice president of translational sciences within the nonclinical safety sciences organization that included oversight of the nonclinical pharmacokinetics and drug disposition, clinical pharmacology, formulation laboratories, and scientific operations. Prior to that, she held several leadership positions at Assay Designs/Enzo Life Sciences from 2007 to 2008, Pfizer’s research and development laboratories from 2001 to 2007, and 3M from 1997 to 2001. Dr. Szekely completed her doctorate in physical chemistry at the Kossuth University in Hungary and Ph.D. in chemistry at Michigan State University.

Matt Young has served as our senior vice president, global operations since October 2022. He previously held positions of vice president and senior director of global operations since joining Glaukos in 2016. Mr. Young has 25 years of experience in the medical technology industry spanning medical devices and drug-device combination products. From 2011 to 2016, he was director of manufacturing operations, engineering and new product introduction with Edwards Lifesciences. Between 2006 to 2011, Mr. Young held several leadership positions in operations and engineering at Abbott Vascular. From 1996 to 2006, he held positions of increasing responsibility at Kimberly-Clark Healthcare, spanning multiple functions including research and development, engineering and operations. Mr. Young holds a B.S. in material science and engineering from the University of Florida and an M.B.A. from the University of Arizona.